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Introduction: 
This case study will examine a patient with a 
rare and disabling movement disorder. The 
primary objective of this essay seeks to criti-
cally analyse and discuss the neuroscience 
nursing care and interventions of multifocal 
motor neuropathy. Firstly, the patients’ clinical 
presentation, past medical history and the 
underlying pathophysiology of multifocal mo-
tor neuropathy will be comprehensively ex-
plored and the epidemiology, etiology and the 
patients’ risk factors will be identified. Sec-
ondly, relevant diagnostic investigations will 
be examined with the goal of identifying the 
interrelationship between the patient’s health 
background and risk factors. Lastly, the nurs-
ing management and treatment for the patient 
will be discussed with a holistic approach, 
taking into consideration the social, ethical 
and psychological effects of the disorder.  
The key aspects that will be discussed in this 
paper will be addressed with the utmost im-
portance placed on maintaining patient confi-
dentiality.  
Case Study: 
A 65-year-old female, who will be referred to 
as Mrs Smith, was admitted to the ward with 
a history of multifocal motor neuropathy first 
diagnosed in 2010 after experiencing left 
hand wasting. A nerve conduction study this 
admission revealed motor block. She had a 
history of hypertension and a previous hip 
replacement, otherwise the patient was gen-
erally well. The patient’s current symptoms 
included limited use of both hands/fingers 
due to significant weakness, pain in hands, 
ulnar muscle wastage and bilateral foot drop. 
The patient had been receiving a mainte-
nance dose 22.5g intravenous immunoglobu-
lin (IVIg) every 4 weeks with a loading dose 
of 120mg once a year. The current admission 
on the ward was for a five-day course of 
120mg of IVIg.  
Multifocal motor neuropathy (MMN) is a slow, 
progressive motor disorder in which the de-
myelination of motor axons occurs (Nowacek 
& Teener, 2012). The likely etiology of MMN 
is an autoimmune attack on the motor nerves 
(Lawson & Arnold, 2014). MMN is an ac-
quired disorder that is associated with elevat-
ed levels of antibodies to ganglioside GM1 
(anti-GM1) and immunoglobulin M (IgM) anti-
bodies (Léger, Guimarães-Costa & Iancu Fer-
foglia, 2015). Studies reveal the link between 
the presence of IgM anti-GM1 antibodies in 
approximately 50% of MMN patients (Vlam et 
al. 2015; Lawson & Arnold, 2014) 
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GM1 is found universally in the body, howev-
er is most abundant in peripheral motor 
nerves (Lawson & Arnold, 2014). GM1 is re-
sponsible for numerous functions including 
paranodal stabilisation and ion channel clus-
tering (Lawson & Arnold, 2014). Disruptions 
to these functions results in conduction fail-
ure across the paranodal regions causing a 
cascading effect on the action potential prop-
agation and leading to conduction failure in 
the peripheral nerves (Lawson & Arnold, 
2014). The abundance of GM1 is found in the 
myelin of motor nerves compared to the sen-
sory nerves, which may provide insight into 
why MMN does not affect sensory nerve 
function (Lawson & Arnold, 2014). The pro-
gressive nature of the disorder is due to auto-
antibodies binding to GM1 gangliosides, acti-
vating the classical complement system path-
way and causing nerve damage by initiating 
the complement membrane attack complex 
within the peripheral nerves (Yuki, Watanabe, 
Nakajima & Spath, 2010). 
 
MMN is a chronic disorder that tends to mim-
ic the more fatal form of movement disorders, 
motor neuron disease (Lawson & Arnold, 
2014). A recent study revealed one third of 
patients are given an initial diagnosis of mo-
tor neuron disease (MND), with further test-
ing eventually ruling MND out (Dimachkie, 
Barohn & Katz, 2013). MMN is considered a 
benign disease, however the functional im-
pairment can have a serious effect on the 
patient’s quality of life (Cats et al. 2010). The 
prevalence of MMN is estimated to affect 1-2 
in 100,000 individuals (Meuth & Kleinschnitz, 
2010). A study has revealed the mean age 
for onset of symptoms is approximately 40 
years old. (Meuth & Kleinschnitz, 2010). As in 
Mrs Smith’s case, the upper extremities are 
usually the first to be affected and most often 
the presenting symptom (Latov, 2014). The 
nerves that are most commonly affected are 
the ulnar, median and radial nerves, with pa-
tients presenting with difficulty extending the 
fingers and wrist and a reduced hand grip 
(Lawson & Arnold, 2014). This is in line with 
Mrs Smith’s initial symptoms. The patient 
currently has restricted movement in both 
hands as well as weakness in her arms and 
lower limbs. MMN causes muscle atrophy 
which is relatively mild in the early stages of 
the disease and worsens as the disease pro-
gresses (Berger, McCallus & Lin, 2013). The 
specific cause of this disorder is still not 
known. A known risk factor is gender, with 
men being twice as likely to develop the dis-
order than women (Sutedja, 2010). Mrs 
Smith does not have any past history or risk 
factors that would indicate that she would be 
at risk of developing the disorder.  
 
To correctly diagnose Mrs Smith, she under-
went nerve conduction studies. Nerve con-
duction studies are considered the gold 
standard, as the test can identify multifocal 
partial conduction blocks (Meuth & Klein-
schnitz, 2010). Motor conduction blocks are 
defined as a decrease of action potentials 
recorded from a specific or group of muscles 
subsequent to proximal nerve stimulation as 
compared with distal nerve stimulation 
(Lawson & Arnold, 2014). MMN affects the 
multifocal partial conduction blocks on motor 
nerves, but not sensory nerves, which is why 
MMN affects the movement of the limbs but 
has no sensory impairment (Yuki, Watanabe, 
Nakajima & Spath, 2010). An international 
study has revealed 80% of MMN patients 
have conduction blocks detected in the ulnar 
nerves and 77% detected in median nerves 
(Cats et al. 2010). Mrs Smith underwent fur-
ther diagnostic imaging including a computed 
tomography scan (CT) of the brain and com-
prehensive blood tests which showed no evi-
dence of disease. However, the nerve con-
duction study revealed a motor block in the 
ulnar and median nerves which confirmed the 
diagnosis of MMN.  
 
Mrs Smith had managed the disorder for 
nearly a decade with effective treatment op-
tions allowing her to maintain independence. 
The treatment Mrs Smith had been receiving 
for the past 6 years was intravenous immu-
noglobulin therapy (IVIg). MMN has no 
known cure, however therapies, such as im-
munoglobulin therapy, aim to reduce motor 
deficits, slow down ongoing axonal degener-
ation and promote remyelination (Léger, 
Guimarães-Costa & Iancu Ferfoglia, 2015). 
IVIg is a solution manufactured from human 
plasma protein (Australian Red Cross, 2018). 
It contains typical IgG antibodies with a broad 
spectrum of antibody activity and is used to 
treat patients requiring antibody replacement 
as well as autoimmune, hematological and 
neurological disorders (Australian Red Cross, 
2018). The mechanism of action of IVIg is not 
fully understood, however it is thought the 
antibodies work against the mechanisms of 
the classical complement pathway in order to 
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prevent the membrane attack (Stangel et al. 
2016). IVIg neutralises pathogenic antibod-
ies, inhibits antibody production by B cells 
and suppresses inflammatory mediators pro-
duced by T cells (Léger, Guimarães-Costa & 
Iancu Ferfoglia, 2015). Several studies prove 
that IVIg has a beneficial long-term effect on 
muscle strength, however it is not able to pre-
vent a small decrease in muscle strength and 
increase of axon loss as the disorder pro-
gresses (Nobile-Orazio & Gallia, 2013; Léger 
et al. 2008). A retrospective study of 40 pa-
tients with MMN found that 68% of patients 
were dependent on long-term maintenance 
IVIg infusions to stabilise their motor condi-
tion (Léger, Guimarães-Costa & Iancu Fer-
foglia, 2015). Most patients will become less 
responsive to IVIg therapy over time and will 
therefore require higher and more frequent 
doses to achieve the result (Lawson & Ar-
nold, 2014). Similarly, another study revealed 
that patients who did not receive IVIg treat-
ment suffered more severe weakness and 
had further progression of axon loss in com-
parison to those patients who received IVIg 
treatment (Jovanovich & Karam, 2015).  
 
The effectiveness of IVIg treatment is de-
pendent on how soon after diagnosis treat-
ment is commenced. A recent international 
study found that 94% of the 88 MMN pa-
tients’ examined responded positively to IVIg 
treatments (Jovanovich & Karam, 2015). The 
6% of MMN patients who did not respond to 
the treatment had been diagnosed with the 
disorder later and their symptoms had be-
come advanced (Jovanovich & Karam, 
2015). Furthermore, the dosage strength and 
frequency of infusions plays a significant role 
in the effectiveness of treatment (Léger et al. 
2008). 
 
Mrs Smith was admitted to the ward for a 
dose of 120g IVIg over five days. The Clinical 
use of Intravenous Immunoglobulin in Aus-
tralia Guidelines recommend IVIg be given 
initially at a 2g/kg dosage over two to five 
days (Australia Red Cross, 2018). This ratio 
accurately correlates with Mrs  Smiths’ 
weight and the prescribed dose of 120g of 
IVIg. A loading dose is common practice 
among practitioners internationally and is 
then followed by maintenance doses of 0.4-
1g/kg every two to four weeks (Australia Red 
Cross, 2018; Schaika et al. 2006). Mrs Smith 
had been receiving maintenance doses of 
22.5g IVIg every four weeks, however in the 
last few months she had reported her symp-
toms becoming more severe. In response, 
her IVIg dose was increased to 24.5g.  
 
As a registered nurse, working within the 
neuroscience department, progressive motor 
disorders are not uncommon and the regis-
tered nurse needs to be able to provide the 
highest quality of care for these patients. It is 
important the neuroscience nurse under-
stands the pathophysiology behind the disor-
der, as well as the correct administration of 
IVIg. IVIg must be given under strict proto-
cols, ensuring the six patient rights are com-
pleted with two nurses and cross checks of 
the product, dose and rate. Reactions to IVIg 
are most likely to occur within the first hour of 
the infusion, therefore the patient must be 
closely monitored and the patient’s vital signs 
checked regularly (Australian Red Cross, 
2018). Common adverse reactions the neuro-
science nurse must be aware of include 
headaches, chills or fever, nausea and vomit-
ing. Mild allergic reactions may occur such as 
skin rash and mild changes to heart rate or 
blood pressure. The neuroscience nurse 
must be aware of severe reactions that may 
occur during transfusion such as; anaphylax-
is, haemolysis, thromboembolic events or 
aseptic meningitis (Hahn et al. 2013). IVIg 
can have a negative effect of the patient’s 
renal function, therefore Mrs Smiths’ renal 
function should have been checked prior to 
commencing the infusion and continued to be 
monitored over the course of five days 
(Lawson & Arnold, 2014).  
 
Along with closely monitoring the patient’s 
vital signs during and after the IVIg infusion; 
the role of the neuroscience nurse is to accu-
rately monitor upper and lower limb strength, 
movement and sensation. The neuroscience 
nurse must also help with mobility and meal 
assistance. It is the role of the neuroscience 
nurse caring for a patient with MMN to advo-
cate for that patient and provide a multidisci-
plinary approach to care, involving the physi-
otherapist and a social worker or discharge 
planner if the patient is struggling to manage 
with their disability. Mrs Smith lived alone and 
was mobilising with a four-wheel walker. An 
occupational therapist offered to assess her 
living conditions to implement further aids 
within the house, however she declined the 
services. Patients with MMN are faced with 
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not only the physical challenges that are at-
tributed to the disorder, but the psychological 
and social effects can negatively affect the 
patient’s quality of life. In 2016, a large inter-
national study revealed 75% of MMN pa-
tient’s felt exhausted and left with no energy 
to complete day time tasks, as well as 59% 
stating they were embarrassed by their limita-
tions (Katz, Lewis & Spatafora, 2017).  
 
Reflection: 
Caring for patients such as Mrs Smith allows 
for improved clinical skills and an in depth 
knowledge of IVIg infusions, which will bene-
fit future patients and provide fellow col-
leagues with a resource of information re-
garding the expected benefits, risks and 
nursing interventions that are associated with 
IVIg infusions.  
 
Conclusion: 
MMN is a rare disorder that purely effects 
motor function. However, due to the disabling 
and incurable nature of the condition, pa-
tients may struggle with emotional and psy-
chological issues. The correlation between 
MMN risk factors and Mrs Smith’s medical 
history was weak, with the patient’s age be-
ing the only known risk factor for her develop-
ing the disorder. There is strong evidence to 
suggest that early treatment of MMN is the 
most important factor in long term functional 
outcome. Fortunately, Mrs Smith was treated 
early and has been responding well to IVIg 
treatment.  
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